Cargando…
Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure
AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observationa...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682855/ https://www.ncbi.nlm.nih.gov/pubmed/37752742 http://dx.doi.org/10.1002/ehf2.14530 |
_version_ | 1785151066500759552 |
---|---|
author | Nomura, Ryohei Morishita, Tetsuji Sato, Yusuke Aoyama, Daisetu Shimizu, Tomohiro Uzui, Hiroyasu Nakano, Akira Tada, Hiroshi |
author_facet | Nomura, Ryohei Morishita, Tetsuji Sato, Yusuke Aoyama, Daisetu Shimizu, Tomohiro Uzui, Hiroyasu Nakano, Akira Tada, Hiroshi |
author_sort | Nomura, Ryohei |
collection | PubMed |
description | AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the ‘early group’. The primary outcome was 48‐h urine volume. The secondary outcomes were in‐hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48‐h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0–31.9 h). Seventy‐four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In‐hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01). CONCLUSIONS: The shorter D2T time did not affect the short‐term urine volume and in‐hospital outcomes but reduced the risk of WRF incidence in patients with AHF. |
format | Online Article Text |
id | pubmed-10682855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106828552023-11-30 Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure Nomura, Ryohei Morishita, Tetsuji Sato, Yusuke Aoyama, Daisetu Shimizu, Tomohiro Uzui, Hiroyasu Nakano, Akira Tada, Hiroshi ESC Heart Fail Original Articles AIMS: We investigated the effects of door‐to‐tolvaptan (D2T) time on short‐term urine volume and in‐hospital clinical outcomes in patients with acute heart failure (AHF). METHODS AND RESULTS: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the ‘early group’. The primary outcome was 48‐h urine volume. The secondary outcomes were in‐hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48‐h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0–31.9 h). Seventy‐four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In‐hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01). CONCLUSIONS: The shorter D2T time did not affect the short‐term urine volume and in‐hospital outcomes but reduced the risk of WRF incidence in patients with AHF. John Wiley and Sons Inc. 2023-09-26 /pmc/articles/PMC10682855/ /pubmed/37752742 http://dx.doi.org/10.1002/ehf2.14530 Text en © 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Nomura, Ryohei Morishita, Tetsuji Sato, Yusuke Aoyama, Daisetu Shimizu, Tomohiro Uzui, Hiroyasu Nakano, Akira Tada, Hiroshi Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
title | Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
title_full | Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
title_fullStr | Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
title_full_unstemmed | Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
title_short | Effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
title_sort | effects of door‐to‐tolvaptan time on short‐term clinical outcome in patients with acute heart failure |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682855/ https://www.ncbi.nlm.nih.gov/pubmed/37752742 http://dx.doi.org/10.1002/ehf2.14530 |
work_keys_str_mv | AT nomuraryohei effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT morishitatetsuji effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT satoyusuke effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT aoyamadaisetu effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT shimizutomohiro effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT uzuihiroyasu effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT nakanoakira effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure AT tadahiroshi effectsofdoortotolvaptantimeonshorttermclinicaloutcomeinpatientswithacuteheartfailure |